Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
XNTR-936
- Development stage
- Preclinical
- Lead developer
- Xennials Therapeutics
- Modality
- Small Molecules
01
Overview
XNTR-936 is a preclinical-stage investigational drug being developed by Xennials Therapeutics. It is a multi-targeted therapeutic construct designed to inhibit Signal Transducer and Activator of Transcription (STAT), the Androgen Receptor N-terminal domain (AR NTD), and Poly ADP Ribose Polymerase (PARP). This multi-pronged approach is intended to disrupt key survival and DNA repair pathways in cancer cells, specifically targeting metastatic hormone-sensitive prostate cancer (mHSPC) and triple-negative breast cancer (TNBC). The drug is part of a pipeline of inhibitors aimed at addressing unmet needs in oncology through the simultaneous modulation of multiple oncogenic drivers.
02
Targets
AR (Adrenergic receptors)PARP (PARP family)STAT (STAT family)
Beyond the preview
Go deeper on XNTR-936.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on XNTR-936.